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Sttmmal'y 
The adhesion interaction between the immunoglobulin superfamily molecules CD2 and CD58 
(lymphocyte function-associated antigen 3) plays an important role in T cell and natural killer 
cell interaction with various antigen-presenting and target cells. Determination of the solution 
structure of rat CD2 domain 1 has allowed a model of human CD2 domain 1 to be generated, 
and a series of mutants based on this model have been made. Residues of domain 1 of human 
CD2 predicted to be solvent exposed were substituted with the equivalent residues present in 
the rat CD2 molecule. The ability of these mutants to mediate rosetting with human and sheep 
erythrocytes was studied. Results show that the binding site of CD2 for both human and sheep 
CD58 maps to the tS sheet containing tS strands CC'C"F and G. Residues K34 and E36 in 13 
strand C, R48 and K49 in/3 strand C', and K91 and N92 in the loop connecting 13 strands 
F and G are shown to be critical in the interaction. The data support the proposition that the 
interaction between CD2 and CD58 involves the major/3 sheet face of CD2. 
T 
he interaction between the CD2 glycoprotein on T lym- 
phocytes and the widely expressed CD58 (LFA-3) mol- 
ecule serves an important role in the T cell immune response. 
CD2/CD58-mediated intercellular adhesion has been shown 
to have a role in the processes of cell-mediated cytotoxicity, 
antigen- and mitogen-induced  T cell proliferation, and lym- 
phokine production (1-4). The interaction was first identified 
as that supporting rosette formation between T lymphocytes 
and sheep or human erythrocytes (5-7). Particular combina- 
tions of mAbs directed against different regions of CD2 in- 
duce signal transduction events that stimulate T cell prolifer- 
ation, as well as T  and NK cell effector functions (8-10). 
These effects can also be obtained by incubation of the cells 
with cell-bound or soluble CD58, or phorbol esters plus cer- 
tain and-CD2 mAbs (11-14). The cytoplasmic domain of CD2 
is essential for the signaling events (15, 16). Signal transduc- 
tion by CD2 requires the presence of a functional TCR/CD3 
complex on T cells and the CD16/~" or Fce receptor 3' com- 
plex on NK cells (17, 18). It has recently been demonstrated 
that CD2 belongs to a T cell activation complex formed by 
the association of the TCR, CD3, CD4, or CD8 and CD5 
surface molecules and intracellular tyrosine kinases  (19). 
The structure of the NH2-terminal domain of rat CD2 
was  initially  determined by  nuclear  magnetic resonance 
(NMR) 2 spectroscopy (20),  and more recently the crystal 
structure of the complete extracellular  part of rat CD2 has 
been reported (21). Both structures have confirmed earlier 
predictions that the extracellular  region of CD2 consisted 
of two immunoglobulin superfamily (IgSF)  domains,  an 
NH2-terminal V-like domain, lacking the usually conserved 
disulphide bridge, and a membrane-proximal C-like domain 
(22,  23). 
Two ligands for human CD2 have been identified so far: 
the CD58 molecule (3) and the complement regulatory pro- 
tein, CD59 (24). A homologne of the CD58 antigen has not 
yet been found in rodents. However, the CD48 molecule has 
been shown recently to be a ligand for CD2, both in the 
mouse (25) and rat (26).  CD2 and its ligands,  CD58 and 
CD48, are closely related molecules that contain two IgSF 
domains (27). They form a subgroup within the IgSF and 
their genes are linked in the genome, indicating that they 
may have evolved by gene duplication (28). 
1 Alan E  Williams died on April 9,  1992. 
2 Abbreviations used in this paper: IgSF, immunoglobulin superfamily; 
NMK, nuclear magnetic resonance. 
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CD2 showed that the NH2-terminal domain of CD2 con- 
tained the binding site for CD58 (29).  This was consistent 
with a random mutagenesis analysis that demonstrated that 
certain residues of domain 1 of CD2 were involved in ligand 
binding (30).  Based on the NMR structure of domain 1 of 
rat CD2, we predicted that the residues of human CD2 shown 
to be involved in the interaction with CD58 (30) were lo- 
cated in/5 strand C' and in the region between/3 strands 
F and G, and it was proposed that the face of the CC'C'FG 
/5 sheet of human CD2 might be involved in ligand binding 
(20).  We have investigated this issue by producing a panel 
of mutants covering many of the surface-exposed residues of 
domain 1 of human CD2. We exploited the fact that rat CD2 
does not form rosettes with sheep or human erythrocytes and 
substituted residues  of human CD2 by the corresponding 
amino acid present in rat CD2. Here we report that all the 
mutations that disrupt the CD2/CD58 interaction lie in the 
CC'C"FG/5 sheet of human CD2. The charged side changes 
of solvent-exposed residues  on B strands C  and C', and on 
the FG loop, appear to play a critical role in the CD2/CD58 
interaction. 
Materials and Methods 
Generation of Human CD2 Mutants.  CD2 mutants were pro- 
duced using a two-step PCR method adapted from that described 
in reference 31, using Taq (Boehringer Mannheim Biochemicals, 
Indianapolis, IN) or Vent (New England Biolabs Inc., Beverly,  MA) 
DNA polymerase. Briefly,  in the the first PCR round, a common 
primer, introducing an XbaI restriction site at the 5' end of the 
human CD2 cDNA, and a series of 21 3' primers were used to 
amplify fragments of domain 1 of human CD2. Each 3' primer 
was specific for a particular strand or loop of CD2 domain 1 and 
contained nucleotide changes such that the PCR product was mu- 
tated with respect to the wild-type template. In a second PCIL 
reaction, the gel-purified  (QIAGEN Inc., Chatsworth, CA) double- 
stranded products of the first PCK amplification were used as 
primers along with a common antisense primer adding an EcoRI 
site in the 3' untranslated region of CD2. The final products ob- 
tained, CD2 mutants flanked  by XbaI and EcoRI restriction sites, 
were gel extracted, subcloned into the pJFE14 expression vector 
(32), and used for transient transfection of COS-7 cells (33). The 
pJFE14 vector, kindly provided by John E  Elliott (University of 
Alberta, Edmonton, Canada), uses the same cloning strategy as 
CDM8 but contains a pBR322 origin of replication, an ampicillin 
resistance gene, and a human T lymphocyte virus type 1 (HTLV-1) 
promoter. The template used in both PCR reactions was the lin- 
earized full-length cDNA of human CD2 in Bluescript KS-, a 
gift from D. Wotton (Imperial Cancer Research Fund, London, 
UK).  The wild-type human CD2 was released from Bluescript 
KS- with EcoRI, blunt ended by treatment with Klenow (Amer- 
sham Corp., Arlington Heights, IL), and ligated into a blunt-ended 
pJFE14 vector. Rat CD2 in CDM8 provided by S. Mallett (MRC 
Cellular Immunology Unit) was used as a control.  Mutants in 
pJFE14 were sequenced using the chain termination method. 
Transfection Of  COS-7 Cells.  COS-7  cells were transfected  using 
the DEAE-dextran procedure (34). Briefly, 1-2  x  107 cells were 
plated and cultured overnight in RPMI 1640 (Gibco, Paisley, UK) 
supplemented with 10% FCS, 2 mM glutamine, and antibiotics 
(50 mg/ml streptomycin sulphate, 100 mg/ml kanamycin, and 50 
mg/ml penicillin  G), and transfected  with 3-5 #g of  plasmid DNA 
of the wild-type or mutant CD2. After 24 h cells were plated into 
two to three 60-mm petri dishes. Expression of the constructs was 
analyzed by indirect immunofluorescence  and flow cytometry 2 d 
posttransfection, and 24 h later the remaining cells were used in 
the rosetting assay described below. 
Anti-CD2 mAbs and Imraunofluorescence Analysis of Transfected 
COS-7 Cells.  The mAbs used in this study were: F92-3All, CLB- 
Tll/1, 95-5-49, and OCH-217 (a gift from F. Gotch, Institute of 
Molecular Medicine, Oxford, UK) (35), and RFT-11 (36), kindly 
provided by M. H. Brown (MRC Cellular Immunology Unit). 
Rat CD2 was detected with the MRC OX-34 mAb. MRC OX- 
21, anti-human C3b inactivator, was used as negative control and 
W6/32 anti-HLA class I as a positive control. Transfected  COS-7 
cells were detached using PBS containing 5 mM EDTA, and in- 
direct immunofhorescence  staining was performed  as described (16). 
Labeled cells were analyzed on a FACScan  |  (Becton Dickinson & 
Co., Mountain View, CA). 
Rosetting Assays.  Human erythrocytes  were obtained  from blood 
of healthy donors, washed three times in PBS, and treated with 
Vibrio cholera neuraminidase (0.025 U/107 cells; Calbiochem- 
Novabiochem Corp., La Jolla, CA) for 45 rain at 37~  The cells 
were then washed twice with PBS and resuspended as a 20% solu- 
tion (vol/vol)  in PBS. Sheep erythrocytes  in Alsevers sohtion (Becton 
Dickinson & Co.) were washed four times in PBS and resuspended 
at 20% (vol/vol) in PBS. Rosetting assays were performed as de- 
scribed (34). Transfected COS-7 cells in 6-cm petri dishes were 
washed twice with PBS and 2 ml of PBS/5% FCS was added to 
each plate, followed  by 0.5 ml of the erythrocyte suspension. Plates 
were incubated at 4~  for 1 h and the nonadherent erythrocytes 
removed by several gentle washes with PBS. 
Molecular Modeling.  A modal of domain 1 of human CD2 was 
generated from the NMR structure of rat CD2 (20) in the ho- 
mology modeling facility of the QUANTA molecular graphics 
package (Molecular Simulations Inc., Burlington, MA). The tor- 
sional angles of residues with differing side chains were adjusted 
to maintain similar orientations in the model. The insertion of two 
residues in the CC' loop was performed by searching a library of 
protein backbone fragments from high-resolution protein crystal 
structures. The stereochemistry and nonbonded contacts of the 
modal were then optimized by two rounds of molecular dynamics 
at 300K and energy minimization. 
Results 
Design of Human  CD2 Domain  1 Mutants.  The three- 
dimensional structure of rat CD2 has been determined both 
by NMR spectroscopy (domain 1) (20) and x-ray crystaUog- 
raphy (21). Assignment of the/5 strands for human CD2 was 
made based on an alignment of the human CD2 sequence 
with that of rat CD2 (Fig. 1; numbering, indicated by dots, 
refers to the human CD2 sequence). A previous mutagenesis 
study predicted, based on an alignment of human CD2 and 
the Ig r  chain, that the adhesion interaction between CD2 
and LFA-3 would involve the regions of CD2 corresponding 
to  the  Ig  hypervariable regions,  and will mimic an  anti- 
body-antigen interaction (30). 
However, in light of the new alignment it was evident that 
the subset of residues  that had been shown both to affect 
CD58 binding (30) and to be solvent exposed (20), indicated 
by circles in Fig. 1, were located in/5 strand C' and in the 
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Figure  1.  Alignment of rat and 
human CD2 extracdluhr region se- 
quences, with the positions  of the 
fl strands determined  from the rat 
CD2 structure  (20, 21) marked by 
a thick overline. (O) Every 10th res- 
idue. Numbering refers to the amino 
acid position of human CD2 with 
respect  to  the  mature  NH2  ter- 
minus  of  the  molecule  (48). 
Residues identical between rat and 
human CD2 are boxed  and those 
previously shown to be involved in 
the CD2/CD58 interaction (30) are 
circled. Solvent inaccessible residues 
of rat CD2 domain 1 are shaded. 
region between fl  strands  F  and  G,  suggesting that  the 
CD2/CD58 interaction might be mediated through the fl 
sheet of CD2 domain 1 containing strands CC'C"F and G. 
A model of human CD2 domain 1, generated from the struc- 
ture of rat CD2 domain 1, was used to design a panel of 
21 mutants to identify the residues of human CD2 that affect 
binding to CD58 and hence estimate the extent of the site 
of interaction.  Amino acids in both fl sheets of human CD2 
at positions  predicted to be solvent exposed were mutated 
because these residues were the most likely to be involved 
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Figure  2.  Expression of human 
CD2 epitopes in wild-type and mu- 
tant CD2. COS-7 cells transfected 
with human CD2 cDNA in pJFE14 
or the indicated mutant were stained 
with anti-CD2 mAbs directed  to 
domain 2 (OCH-217) or domain 1 
(CLB-Tll/1, 95-5-49 and RFT-11) 
of human CD2 (solid lines)  or the 
OX-21 mAb (dotted lines)  as nega- 
tive control. 
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did not rosette with sheep or human erythrocytes, and then, 
to minimize the possibility of major conformational changes 
in human CD2, we substituted human residues with the cor- 
responding amino acid present in rat CD2. Where the residues 
in rat and human were identical a nonconservative substitu- 
tion was used. Mutations were introduced at many of the 
out-pointing positions  in each strand of the two/~ sheets 
and in the loops connecting the/~ strands (Fig. 1). 
Expression of Human CD2 Mutants in COS-7 Cells.  The 
constructs encoding the wild-type and mutant CD2 in the 
pJFE14 eukaryotic expression  vector were transiently expressed 
in COS-7 ceUs. Expression of the mutants was analyzed by 
flow cytometry using a series of anti-CD2 mAbs. The mu- 
tants were stained with at least one antibody binding to do- 
main 1 of human CD2 (F92-3A11, CLB-Tll/1, 95-5-4, and 
tLF-Tll), and the OCH-217 antibody that binds an epitope 
on domain 2 of human CD2 and is weakly expressed  in resting 
T ceUs and transfected COS-7 cells (30). In most cases, and 
always when a mutant failed to bind to one of the antibodies, 
expression was detected with three or more mAbs to rule 
out structural distortion of the molecule or its retention in- 
side the cell FACS  |  profiles of COS-7 cells expressing human 
CD2 and several mutants stained with anti-CD2 mAbs are 
shown in Fig. 2, and the pattern of antibody binding of the 
CD2 mutants is summarized in Table 1. 
Analysis of the Ability of Mutant CD2 Molecules to Interact 
with CD58 by E-Rosetting.  The ability of the mutated forms 
of CD2 to mediate CD58 binding was measured using an 
E-rosetting assay (34). It has been previously shown that anti- 
CD58 mAbs completely inhibit E-rosetting of  CD2-expressing 
cells (6) and that mutations of CD2 that abolish E-rosetting 
also disrupt CD58 binding (12, 37). Monolayers of COS-7 
cells expressing  wild-type or  mutant  human CD2  were 
screened for rosette formation with sheep and neuraminidase- 
treated (Neu +) human erythrocytes. COS-7 ceUs transfected 
with rat CD2 in CDM8 were unable to form rosettes with 
sheep or Neu + human erythrocytes and were used as a nega- 
tive control (Fig. 3 A). There was a dear distinction between 
the mutants that supported rosette formation and those that 
did not, as illustrated in Fig. 3. These data are summarized 
in Table 2. Substitutions  on/~ strands B (N18/T+D20/N 
[17]) and D (K61/E[56]) had no effect on the rosetting ability 
of CD2. Mutations of/3 strand E were not performed be- 
cause most of its residues are buried and therefore unlikely 
to establish interactions with the ligand (Fig. 1). All the mu- 
tations that abolish E-rosetting are located on/~ strands be- 
longing to the CC'C"FG face of CD2. These include substi- 
tution of the charged residues K34 and E36 on/~ strand C 
(Fig. 3 C) and a double mutation in which the positions of 
residues R48 and K49 on strand C' were inverted to KK. 
Consistent with previous results (30), a mutant in which res- 
idue K82 on strand F was changed to an N, present in rat 
CD2,  exhibited  no E-rosetting activity. This substitution 
generates the sequence NVS (residues 82-84) in human CD2, 
which constitutes  an N-glycosylation signal. Interestingly, 
it has been demonstrated that rat CD2 has an N-linked car- 
bohydrate attached to residue N77 (21), the equivalent posi- 
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+  .=.. Figure  3.  Phase  contrast micros- 
copy of E-rosetting of transfected 
COS-7 cells. Cells  transfected  with 
constructs for  rat  CD2, human 
CD2, or mutant CD2 molecules 
were incubated with Neu  + human 
erythrocytes  for 1 h at 4~  and the 
nonadherent erythrocytes washed 
off. Rosettes  were examined under 
light microscope. The location of 
the mutations in the 13 strands or 
loops  of  CD2 domain 1 are indicated 
in parentheses. 
tion  to residue K82 in human  CD2 (Fig.  1).  We therefore 
reasoned that  attachment  of a carbohydrate structure at the 
newly created N-glycosylation site on human  CD2,  when 
expressed in COS-7 cells,  could be responsible for the dis- 
ruption  of the CD2/CD58  interaction.  To test  this possi- 
bility, mutant $84/O~ which had a normal rosetting ability 
(Fig.  3 D), was further mutated,  changing  K82 to N, thus 
preventing the formation of an N-glycosylation signal. The 
double mutant  K82/N[77]+S84/Q formed  rosettes  with 
Neu +  human  erythrocytes (Table 2),  which  strongly  sug- 
gests that residue K82 is not directly involved in CD58 binding 
and that the lack of rosetting ability of the K82/N[77] mu- 
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tant is due to the attachment  of a carbohydrate molecule to 
the face of human CD2 involved in the interaction with CD58. 
A double mutation affecting the loop between strands F 
and G  and  the beginning  of strand  G  (K91/T[86] + N92/ 
R[87])  prevents  the  formation  of  E-rosettes  (Fig.  3  E), 
confirming the importance of this region of CD2 in CD58 
binding (30). The contribution of/3 strand G to the CD2/ 
CD58 interaction was fia'the~ analyzed in two mutants, E95/ 
D[90] and I97/A[92], but both had an unaltered E-rosetting 
ability (Fig. 3 F). The involvement of other loops connecting 
13 strands on the CD2/CD58 interaction was analyzed in sev- 
eral mutants. A deletion mutant in which two lysine residues Table  2.  Panel  of Human CD2 Mutants and Their 
E-rosetting Ability 
Mutant  Strand/Loop  E-rosetting 
N18/T 
D20/N[17] 
D32/E[29] 
K34/R[31] 
K34/D 
E36/R 
K37/R[34] 
T38/G[35] 
K41K42 DEL 
R48/K[43] 
K49/R[44] 
E50/K[45] 
K51/M[46] 
E52/K[47] 
F54/L 
K55/L[50] 
E56/K[51] 
K57/S[52] 
K61/E[56] 
I80/T[75] 
K82/N[77] 
$84/T[79] 
$84/Q 
K82/N[77] 
$84/Q 
K89/N[84] 
K91/T[86] 
N92/R[87] 
E95/D[90] 
I97/A[92] 
B  + 
C  + 
C  + 
C 
C 
C/C'  + 
C/C'  + 
C' 
C'/C"  + 
C ft  -i. 
C"  + 
D  + 
F  + 
F 
F  + 
+ 
F  + 
F/G  + 
F/G 
G  + 
G  + 
Mutants are noted  by the one-htter code  of the amino acid(s) substituted 
and their position(s) in the human CD2 sequence, followed  by a slash, 
and the residue(s)  introduced  with its position[s) in the rat CD2 sequence 
in brackets when applicable. A mutation involving the deletion of two 
amino acids  is noted (DEL). Rosetting  identical  to that of  wild-type  CD2 
is indicated (+), and no detectable rosetting (-). 
(K41K42) were removed from the CC' loop and a double 
mutant (K37/R[34]+T38/G[35]),  affecting the CC' loop, 
showed a wild-type E-rosetting ability (Table 2), suggesting 
that this region is not required for CD58 binding.  In an- 
other mutant the loop connecting strands C' and C" was 
almost entirely substituted by the corresponding rat CD2 
residues  (E50/K[45]+K51/M[46] +E52/K[47]),  and  the 
resulting protein did not show an impairment of its E-roset- 
ting ability. Furthermore, the replacement of the residues 
forming/3 strand C" for either their rat CD2 equivalents 
(K55/L[50] + E56/K[51] + K57/S[52]), or in the case of res- 
idue 54, substitution by L (F54/L) had no effect on erythro- 
cyte binding. From these results we conclude that the CC' 
and C'C" connecting loops and the C"/3 strand, although 
located on the CD58 binding face, are unlikely to be critical 
in the interaction between CD2 and CD58. 
A model of human CD2 domain 1 based on the NMR 
solution structure of rat CD2 domain 1 (20) is shown in Fig. 
4. The human CD2 model exhibits a backbone fold essen- 
tially identical to that of the rat CD2 structure, with no major 
rearrangements of internal residues, which suggests that the 
model should serve as a good basis for the interpretation of 
the mutagenesis results. Fig. 4 A  summarizes the mutations 
described in this and other studies of CD2/CD58  interac- 
tions. In this model the binding site of human CD2 for CD58 
is represented by showing amino acids involved in the CD58 
interaction in red (present study) and orange (reference 30). 
In blue are shown residues that do not affect the CD2/CD58 
interaction Fig. 4 B shows a space-filling representation of 
the CD2 model and shows the residues,  that when mutated, 
affect the rosetting function of CD2 cluster together in a 
surface patch that encompasses the "top" half of the F, C, 
and C'/3  strands as well as residues in the F-G loop. 
Discussion 
Our findings demonstrate that all residues affecting sheep 
and human erythrocyte binding to CD2 are located in the 
five-stranded fl sheet of domain 1 of human CD2, with con- 
tact residues being restricted to strands C  and C' and the 
loop-connecting strands F and G. Mutations in the opposite 
face of the domain (fl strands B and D) do not interfere with 
the interaction. Although it has recently been shown that 
CD59, another molecule expressed on human erythrocytes, 
is able to bind human CD2 (25, 38), other studies have shown 
that the E-rosetting of CD2-transfected COS cells is com- 
pletely blocked by anti-CD58 mAbs (6), making it unlikely 
that the CD2/CD59 interaction is measured by this system. 
The relative contribution of the different regions of the 
interaction face of CD2 is variable. The five-stranded fl sheet 
of CD2 domain I is a highly charged surface, and a number 
of the charged residues are shown to be involved in the inter- 
action. In particular, charged residues K34 and E36 on strand 
C, and K48 and K49 on strand C', are important. The replace- 
ment of residue K34 for its equivalent, R31,  in rat CD2, 
a conservative change that does not alter the charge, has no 
effect on the CD58 binding. In contrast, when residue K34 
is substituted for an acidic residue, D, CD58 binding is corn- 
554  CD2 Binding Site for CD58 Figure 4.  (A) Stereo view ofthe 
model of human CD2 domain 1 
based on the NMR structure of rat 
CD2.  The backbone fold is indi- 
cated in light blue, with the major 
CC'C"FG fl  sheet  to  the  front. 
Amino acid side chains of residues 
that have  been mutated in tither this 
or previous studies are also shown. 
All these side chains are exposed to 
the solvent and their precise  confor- 
mation is indeterminate.  Residues 
previously shown to be involved in 
binding CD58  (reference 30)  are 
shown in orange.  The other side 
chains are residues that have been 
mutated in this study. Residues that 
when  mutated do  not affect the 
CD2/CD58 interaction are shown 
in blue. The side chains of residues 
that when mutated knock out the 
rosetting  function  of  CD2  are 
shown in red.  The side chain  of 
lysine-82, which when mutated to 
asparagine  becomes  a  consensus 
N-linked  glycosylation  site,  is 
shown in yellow. (B) Space-filling 
representation  of  the  complete 
human  CD2  domain  1  model 
shown in the same orientation as A. 
The CD2 binding  site for CD58 has 
been represented:  amino acids in- 
volved in CD58 binding are high- 
lighted  in red.  Residues for those 
mutations in this  study that pro- 
duced no change in CD58 binding 
are shown in blue. The lysine-82  side 
chain is again picked out in yellow. 
pletely abolished. This also applies to residue E36, conserved 
between human  and rat CD2,  in that its  mutation  to the 
oppositely  charged residue R  prevents the CD2/CD58  in- 
teraction. These results show for the first time the involve- 
ment of 3  strand C in CD58 binding.  The loss of rosetting 
when the positions of basic residues R48 and K49 in 3 strand 
C' are inverted is strong evidence that these amino acids are 
contact  residues in the CD2/CD58  interaction. 
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strands C and C' and fl strands C' and C", as well as residues 
in fl strand C", have  no effect on the interaction of CD2 with 
CD58. This suggests that the side chains of these residues, 
although in the fl sheet implicated in CD58 binding, are un- 
likely to be involved in contacts with the CD58 molecule. 
The participation of the loop-connecting strands F and G 
in CD58 binding had been reported (30). Our results extend 
previous  data  by demonstrating that  the mutation K91/ 
T[86] + N92/R[87] blocks binding of CD58. From three mu- 
tations made on fl strand F, only the change K82/N[77] dis- 
rupted CD58 binding. An identical disruptive mutant was 
described by Peterson and Seed (30). However, when residue 
K82 was substituted for an N in the context of  mutant $84/Oo 
the mutant obtained,  K82/N[77]+S84/Q,  was capable of 
E-rosetting.  These results indicate that the disruption of the 
CD2/CD58 interaction observed in mutant K82/N[77] is 
probably due to the attachment of a carbohydrate molecule 
to the new glycosylation site, NVS, generated by the muta- 
tion. This is also supported by the fact that the rat CD2 mol- 
ecule is glycosylated at the equivalent position in strand F 
(21). A similar finding was recently reported for the interac- 
tion of TCR fl chain and the Mls-1  a superantigen (39). The 
presence of an N-linked carbohydrate in the region of Vfl8 
that interacts with Mls-1  a blocks its interaction with the su- 
perantigen. 
In the recently published crystal structure of rat CD2, Jones 
et al. (21) described an interaction between two CD2 mole- 
cules in the crystal. This interaction is mediated by the CC' 
and FG loops and out-pointing residues on all the strands 
forming the CC'C"FG fl sheet, except strand G. The exten- 
sive crystal contact,  although not necessarily representative 
of a physiological molecular interaction, involves some of the 
residues that the mutagenesis results have shown to be crit- 
ical for CD58 binding. 
Mutations that abolish E-rosetting with human erythro- 
cytes also prevent rosetting with sheep erythrocytes, demon- 
strating that the same CD2 residues are involved in the inter- 
action with both human and sheep CD58. This is despite 
the low level (47%) of conservation between the extracd- 
lular region of human CD58 (40) and the 74 amino acids 
known of the extraceUular region of sheep CD58 (T. Hfinig, 
personal communication). It has been proposed that CD2 
and CD58 interact through the CC'C"FG fl sheets of the 
opposed V-like domains, in a manner similar to the two Ig 
V domains of an Fab fragment (41). Determination of the 
complete sequence of sheep CD58 will allow the level of  con- 
servation of the CC'C'~  fl sheet between sheep and human 
CD58 to be assessed and the possibility  of an interaction 
through this  surface to be examined, 
The results presented in this report further demonstrate 
the versatility of Ig domains as recognition structures, with 
evidence accumulating that any surface of an IgSF domain 
may be exploited in both single or multiple adhesion interac- 
tions (42-47).  For example, the CD8 molecule can use the 
CC'C"FG fl sheet to form a dimer with another CD8 mole- 
cule and at the same time is able to interact with the MHC 
class I molecule through the CDR1 and CDR2 equivalent 
regions contained in the BC and C'C" loops (42, 44). Future 
studies will reveal whether additional  surfaces of the CD2 
Ig-like  domains  are involved in interactions  with CD59, 
CD48,  or the CD3 complex. 
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